275 related articles for article (PubMed ID: 27440839)
1. Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications.
Pollack RM; Donath MY; LeRoith D; Leibowitz G
Diabetes Care; 2016 Aug; 39 Suppl 2():S244-52. PubMed ID: 27440839
[TBL] [Abstract][Full Text] [Related]
2. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes.
Yaribeygi H; Atkin SL; Pirro M; Sahebkar A
J Cell Physiol; 2019 Jun; 234(6):8286-8294. PubMed ID: 30417367
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
Esser N; Paquot N; Scheen AJ
Expert Opin Investig Drugs; 2015 Mar; 24(3):283-307. PubMed ID: 25345753
[TBL] [Abstract][Full Text] [Related]
4. Glucose: a vital toxin and potential utility of melatonin in protecting against the diabetic state.
Korkmaz A; Ma S; Topal T; Rosales-Corral S; Tan DX; Reiter RJ
Mol Cell Endocrinol; 2012 Feb; 349(2):128-37. PubMed ID: 22079284
[TBL] [Abstract][Full Text] [Related]
5. Spleen-Derived Anti-Inflammatory Cytokine IL-10 Stimulated by Adipose Tissue-Derived Stem Cells Protects Against Type 2 Diabetes.
Zhang J; Deng Z; Jin L; Yang C; Liu J; Song H; Han W; Si Y
Stem Cells Dev; 2017 Dec; 26(24):1749-1758. PubMed ID: 29032727
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure-lowering effects of incretin-based diabetes therapies.
Lovshin JA; Zinman B
Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
[TBL] [Abstract][Full Text] [Related]
7. Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes.
Herzlinger S; Horton ES
Diabetes Res Clin Pract; 2013 Apr; 100(1):1-10. PubMed ID: 23332049
[TBL] [Abstract][Full Text] [Related]
8. Do not forget that type 2 diabetes does not only expose to cardiovascular complications.
Halimi S
Diabetes Metab; 2014 Jun; 40(3):167-8. PubMed ID: 24751987
[No Abstract] [Full Text] [Related]
9. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.
Lee YS; Jun HS
Mediators Inflamm; 2016; 2016():3094642. PubMed ID: 27110066
[TBL] [Abstract][Full Text] [Related]
10. Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?
Maiorino MI; Bellastella G; Giugliano D; Esposito K
Endocrine; 2017 Feb; 55(2):360-365. PubMed ID: 27230767
[TBL] [Abstract][Full Text] [Related]
11. Incretin therapy for type 2 diabetes mellitus.
Klonoff DC
Adv Ther; 2010 Dec; 27(12):881-94. PubMed ID: 20978879
[TBL] [Abstract][Full Text] [Related]
12. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
13. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis.
Ma J; Yang W; Fang N; Zhu W; Wei M
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):596-603. PubMed ID: 19819121
[TBL] [Abstract][Full Text] [Related]
14. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.
Infante M; Padilla N; Alejandro R; Caprio M; Della-Morte D; Fabbri A; Ricordi C
Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35629988
[TBL] [Abstract][Full Text] [Related]
15. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
[No Abstract] [Full Text] [Related]
16. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
DeFronzo RA
Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular disease and intensive glucose lowering in type 2 diabetes.
Younis N; Soran H; Hassanein M
QJM; 2009 Apr; 102(4):293-6. PubMed ID: 19147659
[No Abstract] [Full Text] [Related]
18. Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options.
Potenza MA; Nacci C; De Salvia MA; Sgarra L; Collino M; Montagnani M
Pharmacol Res; 2017 Jun; 120():226-241. PubMed ID: 28408314
[TBL] [Abstract][Full Text] [Related]
19. Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control.
Scheen AJ; Esser N; Paquot N
Diabetes Metab; 2015 Jun; 41(3):183-94. PubMed ID: 25794703
[TBL] [Abstract][Full Text] [Related]
20. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
